Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
75°
Sunny
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Gossamer Bio, Inc.
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
June 16, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
May 15, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
May 12, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
May 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 13, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
February 03, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
January 28, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 07, 2025
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
November 07, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
August 26, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
May 14, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
May 06, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
May 03, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
March 12, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 05, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
December 13, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
December 05, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.